Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Genet Med ; 23(3): 555-561, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-33214709

RESUMO

PURPOSE: Metachromatic leukodystrophy (MLD) is a lysosomal storage disorder caused by the deficiency of arylsulfatase A (ARSA), which results in the accumulation of sulfatides. Newborn screening for MLD may be considered in the future as innovative treatments are advancing. We carried out a research study to assess the feasibility of screening MLD using dried blood spots (DBS) from de-identified newborns. METHODS: To minimize the false-positive rate, a two-tier screening algorithm was designed. The primary test was to quantify C16:0-sulfatide in DBS by ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). The screening cutoff was established based on the results from 15 MLD newborns to achieve 100% sensitivity. The secondary test was to measure the ARSA activity in DBS from newborns with abnormal C16:0-sulfatide levels. Only newborns that displayed both abnormal C16:0-sulfatide abundance and ARSA activity were considered screen positives. RESULTS: A total of 27,335 newborns were screened using this two-tier algorithm, and 2 high-risk cases were identified. ARSA gene sequencing identified these two high-risk subjects to be a MLD-affected patient and a heterozygote. CONCLUSION: Our study demonstrates that newborn screening for MLD is highly feasible in a real-world scenario with near 100% assay specificity.


Assuntos
Leucodistrofia Metacromática , Cerebrosídeo Sulfatase/genética , Cromatografia Líquida , Humanos , Recém-Nascido , Leucodistrofia Metacromática/diagnóstico , Leucodistrofia Metacromática/genética , Triagem Neonatal , Espectrometria de Massas em Tandem
2.
Mol Genet Metab ; 124(2): 101-108, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29680633

RESUMO

All States screen for biotinidase deficiency and galactosemia, and X-linked adrenoleukodystrophy (X-ALD) has recently been added to the Recommended Uniform Screening Panel (RUSP).We sought to consolidate these tests by combining them into a single multiplex tandem mass spectrometry assay as well as to improve the current protocol for newborn screening of galactosemia.A 3 mm punch of a dried blood spot (DBS) was extracted with organic solvent for analysis of the C26:0-lysophosphatidylcholine biomarker for X-ALD.An additional punch was used to assay galactose-1-phosphate uridyltransferase (GALT) and biotinidase.All assays were combined for a single injection for analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (2.3 min per sample).The GALT LC-MS/MS assay does not give a false positive for galactosemia if glucose-6-phosphate dehydrogenase is deficient.The multiplex assay shows acceptable reproducibility and provides for rapid analysis of X-ALD, biotinidase deficiency, and galactosemia.The throughput and ease of sample preparation are acceptable for newborn screening laboratories.We also show that the LC-MS/MS assay is expandable to include several other diseases including Pompe and Hurler diseases (enzymatic activities and biomarkers).Because of consolidation of assays, less manpower is needed compared to running individual assays on separate platforms.The flexibility of the LC-MS/MS platform allows each newborn screening laboratory to analyze the set of diseases offered in their panel.


Assuntos
Adrenoleucodistrofia/sangue , Biomarcadores/sangue , Deficiência de Biotinidase/sangue , Ensaios Enzimáticos/métodos , Galactosemias/sangue , Triagem Neonatal/métodos , Espectrometria de Massas em Tandem/métodos , Adrenoleucodistrofia/diagnóstico , Adulto , Biotinidase/sangue , Deficiência de Biotinidase/diagnóstico , Teste em Amostras de Sangue Seco , Galactosemias/diagnóstico , Humanos , Recém-Nascido , UTP-Hexose-1-Fosfato Uridililtransferase/sangue
3.
Genet Med ; 22(2): 439-440, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-31570801
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA